Welcome to our dedicated page for Xortx Therapeutics news (Ticker: XRTX), a resource for investors and traders seeking the latest updates and insights on Xortx Therapeutics stock.
XORTX Therapeutics Inc (XRTX) is a clinical-stage biopharmaceutical company advancing therapies for progressive kidney diseases and metabolic disorders. This page serves as the definitive source for verified news, press releases, and regulatory updates related to XRTX's research and strategic initiatives.
Key resources include: Clinical trial developments for conditions like diabetic nephropathy and polycystic kidney disease, partnership announcements with pharmaceutical collaborators, and regulatory milestones. Investors and researchers will find timely updates on xanthine oxidase inhibitor research and uric acid modulation therapies.
Content spans therapeutic advancements, intellectual property updates, and analysis of metabolic disorder treatments. Bookmark this page for structured access to XRTX's progress in addressing complex renal health challenges through evidence-based biopharmaceutical innovation.
XORTX Therapeutics has announced positive topline results from Part 1 of its XRX-OXY-101 Pharmacokinetics Bridging Study, demonstrating a significant increase in oral bioavailability of its proprietary oxypurinol formulations. The trial, which had no adverse events, is a precursor to a planned phase 3 registration trial focused on treating autosomal dominant polycystic kidney disease (ADPKD). Key objectives include determining the optimal formulation and dosing regimen. Part 1 confirmed improved bioavailability and established a pharmacokinetics dataset that aids in future drug development.
XORTX Therapeutics Inc. (NASDAQ: XRTX) has submitted a type B pre-Phase 3 meeting request to the FDA, anticipated in about 70 days. This request follows successful R&D activities for its XRx-008 program targeting autosomal dominant polycystic kidney disease (ADPKD). Key milestones include GMP oxypurinol manufacturing and improved drug formulation. CEO Dr. Allen Davidoff emphasized the meeting's importance for discussing the registration trial protocol and New Drug Application (NDA) for their lead product, which aims to slow renal function decline in ADPKD patients.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced a "Fireside Chat" hosted by CEO Dr. Allen Davidoff on June 22, 2022, at 11 am EST. The session will present updates on innovative therapies aimed at treating progressive kidney diseases, specifically focusing on the company's clinical products: XRx-008 for Autosomal Dominant Polycystic Kidney Disease and XRx-101 for acute kidney injury related to COVID-19. Investors can register for the event through a provided link. XORTX is committed to improving patient quality of life through targeted therapies addressing purine metabolism and uric acid production.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced its participation in the BIO International Convention 2022, from June 13-16, 2022, in San Diego. CEO Dr. Allen Davidoff will present the company's progress and future plans on June 13 at 2 PM. The event aims to enhance outreach to pharmaceutical partners, with over 30 meetings scheduled. XORTX is developing innovative therapies for progressive kidney disease, including XRx-008 for ADPKD and XRx-101 targeting COVID-19 related acute kidney injury. The company focuses on improving patient quality of life.
XORTX Therapeutics, a late-stage clinical pharmaceutical company, announced its participation in the LD Micro Invitational 2022, taking place from June 7-9, 2022. CEO Dr. Allen Davidoff will present on June 8 at 9:25 am PST, providing updates on the company's progress and future plans. XORTX focuses on innovative therapies for progressive kidney disease, with products in development addressing conditions like Autosomal Dominant Polycystic Kidney Disease (ADPKD) and COVID-19 related acute kidney injury. For more details, visit www.xortx.com.
XORTX Therapeutics Inc. has appointed Mr. Anthony Giovinazzo as Chair of the Board of Directors. With over 43 years of experience in the pharmaceutical industry, Giovinazzo aims to bolster XORTX's growth, particularly in advancing the FDA-reviewed drug for kidney diseases into a Phase 3 trial. The company is focusing on developing innovative therapies for progressive kidney disease. Concurrently, XORTX granted stock options to executives, including 150,000 options to Giovinazzo, exercisable at $1.60 over five years.
XORTX Therapeutics Inc. (NASDAQ: XRTX) announced its participation in the H. C. Wainwright Global Investment Conference 2022, held from May 23-26, 2022. Dr. Allen Davidoff, CEO, provided an overview of the company's progress and future plans during the presentation. This event offers a platform to engage with global investors and potential pharmaceutical partners. XORTX is developing innovative therapies aimed at treating progressive kidney diseases, including XRx-008 for Autosomal Dominant Polycystic Kidney Disease and XRx-101 for acute kidney injury related to COVID-19.
XORTX Therapeutics announces that it has received an all-clear notification from the FDA for its IND application concerning the XRX-OXY-101 bridging pharmacokinetics study, supporting its XRx-008 program aimed at treating autosomal dominant polycystic kidney disease (ADPKD).
This approval is pivotal for advancing clinical trials and securing marketing approval for XRx-008, which targets high serum uric acid levels—a critical factor in kidney disease progression. The ongoing study will provide essential data for future regulatory submissions.
XORTX Therapeutics Inc. has successfully completed recruitment for the first part of the XRX-OXY-101 bridging pharmacokinetics study for its XRx-008 program aimed at treating autosomal dominant polycystic kidney disease (ADPKD). A total of 32 subjects have been dosed to evaluate the pharmacokinetics and bioavailability of the proprietary formulations of oxypurinol. The study will also gather essential data for a future 505(b)2 filing. ADPKD affects over 10 million people globally and the company aims to develop therapies to slow kidney function decline.
XORTX Therapeutics has received Small and Medium Enterprise (SME) status in the EU, which will benefit its EMA interactions. This designation offers a 90% fee reduction for various regulatory services, aiding in the upcoming XRX-OXY-301 phase 3 trial for XRx-008. The trial aims to evaluate the safety and efficacy of XRx-008 in patients with ADPKD over 24 months, enrolling an estimated 350 patients. XORTX is also conducting a pharmacokinetics study, XRX-OXY-101, to assess the drug's safety and bioavailability, starting in Q2 2022.
